A Study to Investigate the Effect of Food on Oral LBH589 Absorption in Patients With Advanced Solid Tumors

Phase 1

Completed

• Conditions: Cancer
• Interventions: Drug: LBH589

• Registration Number: NCT00570284
• Lead Sponsor: Novartis Pharmaceuticals

Brief Summary

The primary purpose of this study is to evaluate the effect of food on oral LBH589 in adult patients with advanced solid tumors. This study will also evaluate the safety and efficacy of LBH589 in adult patients with advanced solid tumors

Detailed Description

Not available

Study Timeline

• Study Start: 2007-11
• Study First Submitted: 2007-12-07
• Study First Submitted QC: 2007-12-07
• Study First Posted: 2007-12-10
• Primary Completion: 2011-02
• Study Completion: 2011-02
• Status Verified: 2016-08
• Last Update Submitted: 2020-12-16
• Last Update Posted: 2020-12-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
LBH589	LBH589	-

Primary Outcome Measures

Name	Time	Method
Levels of LBH589 in the blood	every week for the first 3 weeks

Secondary Outcome Measures

Name	Time	Method
Efficacy, Safety and tolerability	throughout study to 28 days after last treatment

Trial Locations

Locations (1)

Novartis Investigative Site; 🇨🇭 Zurich, Switzerland